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We investigated mechanisms underlying progressive axonal dysfunction and structural deﬁcits in type 1BB/Wor-rats from 1week
to 10month diabetes duration. Motor and sensory conduction velocities were decreased after 4 and 6weeks of diabetes and
declinedfurtherovertheremaining9months.Myelinatedsuralnerveﬁbersshowedprogressivedeﬁcitsinﬁbernumbersandsizes.
Structuraldeﬁcits in unmyelinated axonal sizewere evident at 2monthand deﬁcits in number werepresent at 4mo. Thesechanges
were preceded by decreased availability of insulin, C-peptide and IGF-1 and decreased expression of neuroﬁlaments and β-III-
tubulin. Upregulation of phosphorylating stress kinases like Cdk5, p-GSK-3β, and p42/44 resulted in increased phosphorylation
of neuroﬁlaments. Increasing activity of p-GSK-3β correlated with increasing phosphorylation of NFH, whereas decreasing Cdk5
correlated with diminishing phosphorylation of NFM. The data suggest that impaired neurotrophic support results in sequentially
impairedsynthesisandpostranslationalmodiﬁcationsofneuroskeletalproteins,resultinginprogressivedeﬁcitsinaxonalfunction,
maturation and size.
Copyright © 2009 Hideki Kamiya et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Diabetic polyneuropathy (DPN) is a common complication
in diabetic patients. Its pathogenesis is not fully understood
and aspects of underlying mechanisms are controversial
[1, 2]. Although hyperglycemia-induced metabolic abnor-
malities including polyol-pathway hyperactivity, oxidative
stress, protein kinase C alteration and advanced glycation
end-products contribute to type 1 DPN [3, 4], impaired
insulin/C-peptide signaling has emerged as an additional
initiating and important factor in its pathogenesis [2, 5].
Apart from the direct neurotrophic eﬀects exerted by
insulin and C-peptide, they provide gene regulatory func-
tions on other neurotrophic factors and their receptors [6, 7]
with downstream eﬀects on cytoskeletal and cell adhesive
proteins and their postranslational modiﬁcations [8, 9].
Diﬀerences in insulin signaling-related eﬀects are likely to
underlie the diﬀerences between DPN in insulin-deﬁcient
type 1 and hyperinsulinemic type 2 diabetes [1, 10–14].
The characteristic pathological features of DPN are
axonal atrophy and nerve ﬁber loss, secondary to a dying
back process. Early preceding functional deﬁcits are believed
to be metabolically induced by decreased Na+/K+-ATPase
and eNOS activities precipitated by impaired insulin action
and hyperglycemia [1–4, 13]. Axonal changes and nodal
pathology are more severe in type 1 DPN, whereas primary
segmental demyelination is characteristic of type 2 DPN
[2, 8, 11]. In both cases though, DPN is a dynamic disease
process with changing underlying causative pathobiological
components.
Neuroﬁlaments (NFs) and tubulins are major con-
stituents of the axon cylinder and their expression levels and
phosphorylation states determine axonal function, growth
and caliber [13, 15–17]. Studies in animal models have
demonstrated reduced expression of NFs and tubulins in
dorsal root ganglion cells (DRGs), decreased axonal trans-
port of NFs and aberrant phosphorylation of NFs in periph-
eral nerves [18–22]. Since NF mRNAs do not increase during2 Experimental Diabetes Research
development and radial axonal growth, postranscriptional
regulations of NF appear to be more important. Several
neurotrophic molecules, such as nerve growth factor (NGF),
neurotrophin-3 (NT-3), insulin-like growth factor-1 (IGF-
1), insulin and C-peptide stabilize NF transcripts [22, 23].
Aberrant phosphorylation of NFs perturbs their alignment
andinteractionwithothercytoskeletalcomponentsresulting
inimpairedaxonalfunction,andeventuallyatrophyandloss.
Several kinases have been implicated in aberrant phospho-
rylation of NFs, such as cyclin dependent kinase 5 (Cdk5)
and the MAP kinases Erk 1/2 (p44/42), stress-activated
protein kinase/c-jun NH2-terminal kinase (SAPK/JNK) and
phosphorylated glycogen synthase kinase 3β (p-GSK-3β)
[21, 24, 25].
Tubulins are other important cytoskeletal components
assembling into microtubules, which provide a basis for
axonal transport and polarity. Although the role of tubulins
has not been fully explored in DPN, decreased mRNA and
protein expression have been documented [18, 19, 26].
Microtubule-associated proteins such as MAP1B and 120kD
tau regulate the assembly and stability of microtubules
in adult DRGs [27]. An additional protein that binds to
the microtubule plus end is Atk-regulated GSK-β,w h e r e
it regulates a number of microtubule binding proteins
[28]. Inhibition of GSK-β by phosphorylation abolishes
MAP1B phosphorylation and reduces microtubule stability
and axonal outgrowth [29].
Previous studies have emphasized the importance of
cytoskeletal proteins for axonal function, whereas their
relationship to axonal growth, pathology and nerve mor-
phometry has not previously been examined longitudinally
in experimental diabetes. Most studies have examined STZ-
induced diabetic rats [18–22], a model in which structural
changes in peripheral nerve are mild and which does not
display progressive nerve ﬁber deﬁcits.
TheinsulinopenicBB/Wor-rat,isaclosemodelofhuman
type 1 diabetes [30] and shows early structural changes
followed by loss of myelinated and unmyelinated ﬁbers as
in the human condition [9, 31]. To explore the sequential
and mechanistic role of neuroskeletal protein perturbations
in the course of DPN development, diabetic BB/Wor-rats
were investigated longitudinally from 1-week to 10-month
duration of diabetes. We examined motor, sensory and
C-ﬁber functions, quantitative structural abnormalities of
myelinatedandunmyelinatedﬁbersinsuralnerve,cytoskele-
tal protein expression, their phosphorylation as well as the
expression of phosphorylating kinases in DRGs.
2.MaterialsandMethods
2.1. Animals. Male prediabetic BB/Wor-rats and age- and
sex-matched nondiabetes prone BB-rats were obtained from
Biomedical Research Models (Worcester, MA). Body weight,
urine volume and glucosuria (Keto-Diastix, Bayer, Elkhart,
IN) were monitored daily to ascertain onset of diabetes and
for calibrating daily insulin doses. After onset of diabetes at
76 ± 4d a y so fa g e ,d i a b e t i cr a t sr e c e i v e dt i t r a t e dd o s e s( 0 . 4 –
3.3U/d) of protamine zinc insulin (Blue Ridge Pharmaceu-
ticals, Greensboro, NC) to maintain constant blood glucose
levels at approximately 25mM and to prevent ketoacidosis.
As previously demonstrated this paradigm maintains the
animals well above (>15.0mM) hypoglycemic levels [32].
Animals were cared for in accordance with the guidelines of
the Animal Investigation Committee, Wayne State University
and those of NIH (publication no. 85-23, 1995).
2.2. Thermal Plantar Test. Latencies of hind paw withdrawal
to thermal stimulation (42◦C; 152mW/cm2) were used as
measures of thermal algesia, reﬂecting unmyelinated ﬁber
function, and were measured at 1-week, 1-week, 2-week,
4-week, 7-week and 10-month duration of diabetes. The
measurements were performed using a UGO Biological
Research Apparatus (Comerio, Italy). The time from heat
source activation to the animal’s self-withdrawal in seconds
was measured six times in alternating hind paws. The mean
of these measurements was calculated and used as the
individual measure of latency withdrawal [33].
2.3. Electrophysiological Recordings. For nerve conduction
velocities studies, animals were anesthetized with isoﬂurane
inhalation (2-3%) mixed with oxygen delivered by an
anesthesia machine system. Motor nerve conduction velocity
(MNCV) and sensory nerve conduction velocity (SNCV)
were measured in the left hind limb under temperature
controlled (36-37◦C) conditions using a Cadwell 5200A
Electromyographer (Cadwell Laboratories, Kennewick, WA)
as previously described in detail [8, 12, 26]. MNCV was
measuredat1-week,1-week,2-week,4-week,7-weekand10-
month duration of diabetes and SNCV at 6week, 2-week, 4-
week, 7-week and 10-month.
2.4. Tissue Collection. After 2, 4, 7 and 10-month of dia-
betes, diabetic and age-matched control rats were sacriﬁced
with an intraperitoneal overdose of sodium pentobarbital
(120mg/kg body weight). The right unifascicular sural nerve
was dissected from ﬁve diabetic and ﬁve control rats at
e a c ht i m ep o i n ta n dﬁ x e di n1 %c a c o d y l a t eb u ﬀered (pH
7.4) 2.5% glutaraldehyde, dehydrated and embedded in
Epon for morphometric analyses as previously described
(6,35). Bilateral L4 and L5 DRGs from four animals per
group at 2, 7, and 10-month of diabetes were collected
for protein extraction. Tissues were snap frozen in liquid
nitrogenandkept in −80◦Cuntil use.Animals wereperfused
with 500mL of 0.1M phosphate buﬀered (pH 7.4) 4%
paraformaldehyde. L4 and L5 DRG’s were postﬁxed in the
sameﬁxative,rinsedinPBS,dehydrated,immersedinxylene,
embedded in paraﬃn and used for immunocytochemical
studies.
2.5. Western Blotting. DRGs were lysed in detergent lysis
buﬀer (50mM Tris-HC1, pH 7.4, 150mMNaCl, 1mM
EDTA, 1% Triton X-100, 1mM phenylmethylsulfonyl
ﬂuoride, 1μg/mL leupeptin and 1μg/mL aprotinin). The
lysates were centrifuged at 12,000rpm for 20 minutes
at 4◦C and protein concentrations were measured using
bicinchoninic acid protein assay reagent (Pierce, Rockford,
IL) with bovine serum albumin as standard. Ten to 40Experimental Diabetes Research 3
μg of protein was separated by 7.5–10% SDS-PAGE, and
transferred to PVDF membranes (Bio-Rad, Hercules, CA).
Membranes were blocked with Tween-20-tris buﬀered
saline (TTBS) (10mM Tris-HC1, pH 7.5, 100mMNaCl
and 0.1% Tween 20) containing 5% nonfat dry milk
(Bio-Rad, Hercules, CA) prior to incubation with primary
antibodies. Primary antibodies were: Rabbit-polyclonal-
antineuroﬁlament heavy (C-terminal), rabbit-polyclonal-
antineuroﬁlamentmedium(C-terminal),rabbit-polyclonal-
antineuroﬁlament light, mouse-monoclonal-anti-β-III
isoform of tubulin and mouse-monoclonal-antiactin were
all purchased from Chemicon International (Temecula,
CA). Mouse-anti-β tubulin was from Oncogene Research
(Cambridge, MA). Rabbit antiphospho tau antibodies (PS
396 and PS 404) were gifts from Dr. K. Ishiguro, Mitsubishi
Kagaku Institute of Life Sciences, Tokyo, Japan. Mouse-
monoclonal-antineuroﬁlament-phosphorylataed epitope
(SMI31) was from Covance Research Products (Berkeley,
CA), rabbit-polyclonal-phosphorylated p44/42 MAP kinase
(Thr202/Tyr204), rabbit-polyclonal-total p44/42 MAP
kinase, mouse-monoclonal-antiphosphorylated SAPK/JNK
(Tyr180/Tyr182) and rabbit monoclonal antiphospho
p38 were from Cell Signaling Technology (Danvers,
MA). Goat-polyclonal-anti-GSK-3β and p-GSK-3α/β
was from Santa Cruz Biotechnology (Santa Cruz, CA),
and rabbit-polyclonal-anti-Cdk5 was from Abcom Inc.
(Cambridge, MA). Antigen detection was performed
using chemiluminescence (Amersham Pharmacia Biotech,
Piscataway, NJ) with horseradish peroxidase-conjugated
secondary antibodies. Membranes were exposed to Biomax
ﬁlm (Kodak, Rochester, NY). Images were scanned and
densities determined by a Bio-Rad Fluoro-S multimager
(Bio-Rad, Hercules, CA). Expression of proteins was
corrected for by actin density and expression in control
animals was arbitrarily set to 1.0.
2.6. Morphometry. Semithin (0.5μm) cross-sections of
Epon-embedded sural nerves were stained with toluidine-
blue for light microscopic morphometric analysis using a
computerized image analysis system (Image-1, Universal
Imaging Corp, West Chester, PA). This system is pro-
grammed to assess the total complement of sural nerve
myelinated ﬁbers and provides the following parameters:
number of ﬁbers (#), ﬁber density (#/mm2), mean ﬁber area
(μm2), mean axonal area (μm2), mean myelin area (μm2),
axon/myelin ratio, index of circularity and ﬁber occupancy
rate (% of total fascicular area) as previously described
[34].
For morphometric analyses of unmyelinated ﬁbers,
ultrathin cross sections of sural nerves were obtained from
a LKB ultramicrotome (Marviac Limited, Halifax, Canada)
and stained with uranyl acetate and lead citrate. They were
examined in a Zeiss EM 900 electron microscope (Carl
Zeiss,Oberkochen,Germany).Systematicallyselectedframes
representing 25 to 30% of the sural nerve cross-sectional
area were obtained. Photographs were enlarged 10,000
times and downloaded to the image analysis system. The
following morphometric parameters of unmyelinated ﬁbers
were obtained: unmyelinated ﬁber number, ﬁber density
(#/mm2), mean ﬁber size (μm2), axon numbers per Schwann
cell unit and the frequencies of collagen pockets, denervated
Schwann cell proﬁles, type 2 axon-Schwann cell relationship
(disruption of the mesaxon) and regenerating C-ﬁbers
[33].
2.7. Immunostaining. Deparaﬃnized 6μms e c t i o n so fD R G s
were incubated with selected primary antibodies (Cdk5,
GSK-3β and SMI-31, same sources as above) for 30 minutes
at room temperature, washed with three changes of PBS, and
incubated with peroxidase-conjugated secondary antibodies
(Vector Lab, Burlingame, CA) for 30 minutes at room
temperature. The immunoreactive products were visualized
with DAB as color chromogen.
2.8. Statistical Analysis. A l lv a l u e sw e r ee x p r e s s e da sm e a n s
± SD. Signiﬁcance of diﬀerences was analyzed by ANOVA.
Group diﬀerences were assessed by Scheﬀes test. Signiﬁ-
cance was deﬁned as a P-value less than .05. To assess
the relationship between expression of stress-kinases and
hyperphosphorylation of individual neuroﬁlaments linear
or logistic regression analyses were performed. All analy-
ses were performed by personnel unaware of the animal
identities.
3. Results
3.1. Clinical Findings. Blood glucose and glycated
hemoglobin levels were consistently and signiﬁcantly
(P<. 001) elevated in diabetic rats. Plasma insulin
levels were markedly reduced (P<. 001) throughout the
observation period. As a reﬂection of pancreatic β-cell loss,
C-peptide levels were severely decreased or not measurable.
Plasma IGF-1 levels were signiﬁcantly decreased already in
2-month diabetic rats (P<. 001) and remained decreased
compared to control values (Table 1).
3.2. Latencies to Thermal Stimulations. Hyperalgesia, as
reﬂected by decreased withdrawal latencies, was signiﬁcantly
(P<. 001) altered at 1-month of diabetes. Latencies
decreased up to 4-month of diabetes, then plateaud and
increased (P<. 001) from 7 to 10-month of diabetes, at
which time it was not diﬀerent (P = .07) from that of control
animals (Figure 1(a)). The increase in latencies from 7 to 10-
month most likely represent increasing hypoalgesia due to
progressive C-ﬁber deﬁcits (see below).
3.3. Motor Nerve Conduction Velocity (MNCV). MNCV was
normal at one-week of diabetes, however, it was signiﬁcantly
(P<. 05) decreased at one month and decreased progres-
sively thereafter to reach 68% (P<. 001) of normal values at
10-month of diabetes (Figure 1(b)).
3.4. Sensory Nerve Conduction Velocity (SNCV). Only after
6wks of diabetes did diabetic rats show a signiﬁcantly (P<
.05)reducedSNCV,adeﬁcitthatincreasedprogressivelywith
duration of diabetes to reach 78% (P<. 001) of normal
values at 10-month (Figure 1(c)).4 Experimental Diabetes Research
Table 1: Clinical data.
N Body weight (g) Blood glucose level (mM) Insulin pmol/L C-peptide pmol/L IGF-1 ng/mL
2-month Control 8 428 ± 19 5.0 ± 0.4 455 ± 52 710 ± 52 1785 ± 112
BB/Wor 8 348 ± 21∗ 24.6 ± 2.2∗ 57 ± 7∗ 43 ± 12∗ 1328 ± 87∗
4-month Control 8 429 ± 22 5.0 ± 0.3 438 ± 27 723 ± 12∗ —
BB/Wor 8 375 ± 15† 23.9 ± 1.3∗ 51 ± 6∗ <25∗ —
7-month Control 9 505 ± 37 5.3 ± 0.3 526 ± 108 727 ± 24 1182 ± 32
BB/Wor 9 370 ± 18∗ 25.2 ± 1.7∗ 153 ± 55∗ <25∗ 778 ± 70∗
10-month Control 8 555 ± 29 5.0 ± 0.3 506 ± 81 687 ± 18 1192 ± 37
BB/Wor 8 400 ± 13∗ 23.2 ± 1.3∗ 84 ± 21∗ <25∗ 747 ± 86∗
Results are means ± SD. †P<. 01; ∗P<. 001 versus respective control-rats.
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Figure 1: (a) Latencies of thermal plantar tests of control and diabetic BB/Wor-rats at 1-week, 1-month, 2-month, 4-month, 7-month and
10-month duration. (b) Motor nerve conduction velocity of control and diabetic BB/Wor-rats at 1-week, 1-week, 2-week, 4-week, 7-week
and 10-month duration; (c) Sensory nerve conduction velocity of control and diabetic BB/Wor-rats at 6week, 2-week, 4-week, 7-week and
10-month duration. Results are means ± SD (n = 8) ∗P<. 05, ∗∗P<. 01 and ∗∗∗P<. 001 versus respective control values.
3.5. Myelinated Fiber Morphometry of the Sural Nerve
(Table 3). Only a slight decrease (P<. 05) in the circularity
ofmyelinatedaxonswasevidentat2-monthofdiabetes.Four
month diabetic rats showed a signiﬁcant deﬁcit in axonal
size (P<. 005) of myelinated ﬁbers (Table 2). After 7-month
of diabetes, there was a robust diﬀerence (P<. 001) in
ﬁ b e rs i z ed u et oa x o n a l( P<. 001) and myelin (P<. 005)
atrophy compared to control rats, which was reﬂected in
a further decrease in the index of circularity (P<. 001)
(Table 2). The most striking change though was a 15% (P<
.005) deﬁcit in myelinated ﬁber number. This progressed
to 30% (P<. 001) at 10-month of diabetes (Figure 2(a)),
which was reﬂected in a decreased (P<. 05) occupancy rate
(Table 2).Experimental Diabetes Research 5
3.6. Unmyelinated Fiber Morphometry. Two month dia-
betic animals showed mild (P<. 05) growth deﬁcits of
unmyelinated ﬁbers which became more pronounced to
reach 72% (P<. 005) of normal values at 10-month of
diabetes (Table 3). Moreover there were signiﬁcant deﬁcits
in unmyelinated ﬁber numbers from 4-month of diabetes
onwards (P<. 001), which amounted to 56% (P<. 001) at
10-month of diabetes (Figure 2(b)). These deﬁcits were pre-
ceded and accompanied by signiﬁcant degenerative changes,
such as increased frequencies of type 2 Schwann cell/axon
relationship(disruptionofthemesaxon)(P<. 001),collagen
pockets (P<. 01) and denervated Schwann cell proﬁles (P<
.001). Concomitant with ongoing degeneration, diabetic rats
showed increased rates of regenerating C-ﬁbers (Table 3).
3.7. Expression of NFH, NFM and NFL and Phosphorylation
of NFH and NFM. NFH expression showed two major
bands at molecular weights 180kd and 200kd. In 2, 7
and 10-month diabetic rats NF-H expression in DRGs of
both 180kd (P<. 05, P<. 005 and P<. 001, resp.)
and 200kd (P<. 05, P<. 005 and P<. 005, resp.)
were signiﬁcantly and progressively decreased (Figure 3(a)).
The decreased expression of NF-M at 2-month of diabetes
remained relatively constant over the 10-month course (P<
.005, P<. 005 and P<. 05 resp.) (Figure 3(b)). The
decreased expression of NF-L also remained constant (P<
.05, P<. 05 and P<. 05) in diabetic DRGs at 2, 7
and 10-months respectively (Figure 3(c)). With the speciﬁc
antibody, SMI 31, phosphorylated NFH and NFM were
detected. There was no absolute change in phosphorylated
NFH during the observation period, whereas a doubling
(P<. 05) of phosphorylated NFM occurred at 2-month
of diabetes and then declined (Figure 3(d)). On the other
hand, the proportion of phosphorylated NFM relative to
NFM expression was increased in 2-month (P<. 001), 7-
month (P<. 005) and 10-month (P<. 05) diabetic rats
(Figure 3(e)i). Therefore, the proportion of phosphorylated
NFM decreased with duration of diabetes. The ratios of
phosphorylated NFH, calculated as the proportion of total
NFH expression, were signiﬁcantly increased in 2, 7 and 10-
months of diabetic rats (P<. 0 5 )a n dt e n d e dt oi n c r e a s e
with duration of diabetes (Figure 3(e)ii). The expression of
phosphorylated tau (PS 396 and PS 404) was not altered in
diabetic rats for any of the epitopes (data not shown).
3.8. Expression of Tubulin in DRGs. Neuron speciﬁc βIII-
tubulin levels were reduced in diabetic animals at 2, 7, and
10-month (P<. 05, P<. 001, P<. 005, resp.) (Figure 3(f)),
whereas total β-tubulin levels were not altered at any time
point (Figure 3(g)).
3.9. Phosphorylation of MAPKs in DRGs. There were signiﬁ-
cant increases in phosphorylated p42 (Erk 2) in DRGs at 2, 7
and 10-months of diabetes (P<. 05, P<. 005 and P<. 01,
resp.) and phosphorylated p44 (Erk 1) (P<. 05, P<. 001
and P<. 01, respectively) (Figure 4(a)), whereas total p42
and p44 levels did not change (Figure 4(b)).The proportions
of phosphorylated p44 (P<. 01, P<. 005 and P<. 05, resp.)
andp42(P<. 01,P<. 005andP<. 005,resp.)weretherefore
increased in 2,7 and 10-month diabetic rats (Figures 4(e)i
and 4(e)ii). Both 46kd and 54kd phosphorylated SAPK/JNK
levels in DRGs were unchanged in 2 and 7-month diabetic
rats, but signiﬁcantly increased in 10-month diabetic rats
(both P<. 05) (Figure 4(c)). Phosphorylated p38 was not
altered in 2-month diabetic rats, but increased in 7-month
diabetic rats (P<. 01) and returned to normal at 10-month
(Figure 4(d)).
3.10. p-GSK-3β and Cdk 5 in DRGs. Cdk5 showed a more
than four-fold increase (P<. 001) in 2-month diabetic rats
and then declined at 7-month (P<. 05) and declined further
to below control values (P<. 05) at 10-month (Figure 5(a)).
Total GSK-3β was not altered throughout the observation
period (Figure 5(b)), whereas p-GSK-3β increased gradually
with duration of diabetes (Figure 5(c)). It was modestly
increased (P<. 05) in 2-month diabetic rats, but increased
further at 7 (P<. 01) and 10-month (P<. 001) duration
of diabetes (Figure 5(a)). This resulted in an increasing pro-
portion of GSK-3β being phosphorylated (Figure 5(d)). p-
GSK-3β correlated linearly with increasing phosphorylation
of NFH (P<. 002) (Figure 5(e)). Signiﬁcant correlation
(P<. 002) existed between decreasing expression of Cdk5
and the decreasing proportion of phosphorylated NFM over
the course of diabetes (Figure 5(f)).
3.11. Immunohistochemistry. Immunostaining for Cdk5
showed frequent positive staining of small DGR neurons
and their nuclei in 2-month diabetic rats, which decreased
with duration of diabetes (Figure 6(a)). Only sporadic
GSK-3β-positive neurons were present in 2-month diabetic.
In 10-month diabetics there was a general positivity of both
small and large DRG neurons (Figure 6(b)).
4. Discussion
Here we show that early deﬁcits in insulin and C-peptide
availability and decreased presence of IGF-1 as well as
hyperglycemia are associated with impaired functions of
unmyelinated and myelinated nerve ﬁbers. Such changes
are accompanied in DRGs by perturbations of the IGF-1
and insulin receptors, transcription factors such as NF-κB
and early gene response factors such as c-fos perpetuating
impaired protein expression of neuroﬁlaments and β-III
tubulin [7, 26, 35, 36]. Consequent decreases in insulin
and IGF-1 signaling activities enhance the expression of
so-called stress kinases such as p-GSK-3β, p42/44, Cdk5
and SAPK/JNK with aﬃnities to cytoskeletal elements [37].
Resulting malalignment and disassembly of interactive neu-
roﬁlaments and tubulins result in progressively impaired
axonal growth, atrophy and eventually axon loss. This
sequence of events appears to aﬀect unmyelinated ﬁbers
earlier and more severely than myelinated ﬁbers paralleling
theearlyimpairedneurotrophicsupportbyinsulinandNGF,
which target speciﬁcally small DRG neurons [19, 33, 38, 39].
The initial functional deﬁcits of unmyelinated ﬁbers
are most likely due to hyperexcitability of C-ﬁbers through6 Experimental Diabetes Research
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Figure 2: Longitudinal morphometric data showing myelinated and unmyelinated ﬁber numbers. Note increasing deﬁcits in both
myelinated and unmyelinated ﬁbers in diabetic rats compared to age-matched control rats. However the absolute ﬁber numbers in diabetic
rats did not change over the observation period, suggesting a component of impaired ﬁber maturation in diabetic animals. ∗P<. 05,
∗∗P<. 01, ∗∗∗P<. 001 versus age-matched control values.
Table 2: Myelinated ﬁber morphometry.
2-month
control
2-month
BB/Wor
4-month
control
4-month
BB/Wor
7-month
control
7-month
BB/Wor
10-month
control
10-month
BB/Wor
Fiber area
(μm2) 30.9 ± 2.6 30.7 ± 3.3 36.2 ± 3.8 32.5 ± 3.6 41.7 ± 1.0 33.3 ±
2.3∗∗∗∗ 38.9 ± 2.0 31.4 ±
1.5∗∗∗∗
Axon area
(μm2) 11.7 ± 1.0 11.5 ± 1.9 15.0 ± 1.6 11.9 ± 1.4∗∗∗ 18.5 ± 0.5 13.6 ±
1.4∗∗∗∗ 16.2 ± 1.1 12.4 ±
0.8∗∗∗∗
Myelin area
(μm2) 19.2 ± 2.0 19.2 ± 1.8 22.1 ± 2.4 20.4 ± 1.3 24.8 ± 2.1 19.7 ± 1.6∗∗∗ 22.7 ± 1.7 19.0 ± 1.5∗∗
a/m ratio 0.613 ± 0.063 0.601 ± 0.079 0.655 ± 0.119 0.624 ± 0.084 0.750 ± 0.065 0.692 ± 0.079 0.716 ± 0.069 0.654 ± 0.071
OR (%) 49.8 ± 7.6 46.6± 4.2 49.7 ± 3.5 52.4± 3.6 61.3 ± 3.7 58.3 ± 1.8 57.9 ± 4.7 50.0 ± 5.8∗
I.C. 0.955 ± 0.012 0.926 ±
0.023∗ 0.937 ± 0.013 0.906 ± 0.017 0.946 ± 0.005 0.900 ±
0.007∗∗∗∗ 0.924 ± 0.011 0.895 ±
0.026∗
Results are means ± SD. ∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 005 and ∗∗∗∗P<. 001 versus respective control rats.
Table 3: Unmyelinated ﬁber morphometry.
2-month
control
2-month
BB/Wor
4-month
control
4-month
BB/Wor
7-month
control
7-month
BB/Wor
10-month
control
10-month
BB/Wor
Axon
number/SC
(#/unit)
5.01 ± 0.81 4.47 ± 0.54 5.26 ± 0.64 4.22 ± 0.29∗ 5.29 ± 0.26 4.17 ±
0.11∗∗∗∗ 5.20 ± 0.34 4.03 ±
0.26∗∗∗∗
Mean ﬁber area
(μm2) 0.636 ± 0.076 0.534 ±
0.049∗ 0.742 ± 0.090 0.613 ±
0.042∗ 0.706 ± 0.072 0.531 ±
0.044∗∗∗ 0.676 ± 0.056 0.487 ±
0.076∗∗∗
Denervated SC
(%) 0.08 ± 0.11 0.86 ±
0.40∗∗∗ 0.24 ± 0.18 0.97 ±
0.26∗∗∗ 1.00 ± 0.32 2.61 ±
0.57∗∗∗∗ 2.54 ± 0.90 4.42 ± 1.32∗
Collagen pocket
(%) 0.76 ± 0.35 1.95 ± 0.78∗ 0.62 ± 0.42 1.59 ± 0.57∗ 1.65 ± 0.32 3.15 ± 0.89∗∗ 7.98 ± 0.49 11.60 ± 3.36∗
Type 2
relationship (%)2.21 ± 0.40 4.29 ±
0.91∗∗∗ 1.18 ± 0.13 6.45 ±
2.00∗∗∗∗ 3.30 ± 0.54 14.45 ±
3.02∗∗∗∗ 6.04 ± 1.47 18.22 ±
2.36∗∗∗∗
Regenerating
ﬁber (%) 0.84 ± 0.39 1.59 ± 0.32∗∗ 0.56 ± 0.43 2.07 ±
0.36∗∗∗∗ 1.69 ± 0.51 2.49 ± 0.46∗ 4.28 ± 1.24 8.56 ± 3.13∗
Results are means ± SD. ∗P<. 05; ∗∗P<. 01; ∗∗∗P<. 005; and ∗∗∗∗P<. 001Experimental Diabetes Research 7
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1 ±0.2 0.33 ± 0.1
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∗ ∗∗
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∗∗∗
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180 kd
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64 kd
49 kd
1±0.08 ±0.04 1± 0.07 ± 0.12 1±0.09 ±0.08 1.03 0.99 0.95
(g)
37 kd
49 kd
1±0.08 ± 0.04 1± 0.05 ±0.08 1±0.04 ±0.07 0.95 1.06 1.07
(h)
Figure 3: Levels of phosphorylated and total neuroﬁlament subunits in DRGs. (a) total NFH; (b) total NFM; (c) total NFL; (d) SMI31
(phosphorylated NFM and NFH); and (e) Relative phosphorylation of NFM (ei) and NFH (eii) at 2-month, 7-month and 10-month of
diabetes. Results are means ± SD (n = 4). ∗P<. 05, ∗∗P<. 005 and ∗∗∗P<. 001 versus respective control rats. Expression of DRG tubulins.
(f) betaIII-tubulin, (g) total beta-tubulin and (h) actin levels in DRGs at 2-month, 7-month and 10-month diabetic rats. Results are means
± SD (n = 4) ∗P<. 05, ∗∗P<. 005 and ∗∗∗P<. 001 versus respective control rats.
increased activation of tetrodotoxin-resistant Na-channels
[40, 41]. In myelinated ﬁbers the early and reversible nerve
conduction deﬁcits have been related to insulin deﬁciency-
and hyperglycemia-related suppression of nodal Na+/K+-
ATPase activities [1, 3, 8].
As shown previously in this model, impaired availability
of insulin and C-peptide aﬀects the gene expression of IGF-
1, NGF and NT-3 and their receptors [23, 36, 42]w i t h
consequences for the expression of neuroskeletal proteins
[43, 44]. NFs are unique to neurons and interact with
microtubules and other cytoskeletal elements and form the
basis for axonal transport. NFs consist of three intermediate
ﬁlament proteins, NFL (61kD), NFM (90kD) and NFH
(110kD). They have a central domain in common involved
in the formation of coiled-coil dimers. Two dimers align in
a staggered fashion to form tetramer and eventually 10nm
ﬁlaments[15].TheformationofNFheteropolymersrequires
NFL to aggregate with either NFM or NFH [45]. NFL
and NFM are coordinately expressed suggesting the same
transcriptional signals, whereas NFH is regulated separately
[46]. During their assembly in the perikaryon, NFL acts
as the core and NFM and NFH become phosphorylated as
the coil leaves the perikaryon, important for the formation
of cross-bridges, intraﬁlament spacing, axonal growth and
conduction velocity [47].
Here we demonstrate marked suppression in the coordi-
nately expressed NFL and NFM at 2-month, which remained
constant, whereas NFH expression declined with duration of
diabetes. Initially, 78% of NFM showed aberrant phospho-
rylation, which decreased with duration of diabetes. On the
otherhandtheproportionofphosphorylatedNFHincreased
with diabetes duration to reach 1.7-fold at 10-months
duration.Theseﬁndingsindicatethatimpairedassemblyand
function of NFs occur early in diabetic neuropathy initiated
by aberrant phosphorylation of NFM followed by increasing
phosphorylation of NFH. The aberrant phosphorylation can
be correlated with generation of stress-kinases secondary to
impaired insulin and IGF-1 signaling. These changes alone
are likely to perturb the interactions with tubulins. Several
stress-related kinases have been identiﬁed as being respon-
sible for aberrant neuroﬁlament phosphorylation [21]. The
early increase in p35 regulated Cdk5 is likely to underlie
early phosphorylation of speciﬁc neuroﬁlament side arm
fragments [48], as indicated by the decreasing expression
of Cdk5 with duration of diabetes paralleling decreasing
phosphorylation of NF-M. Immunoreactivity of Cdk5 in 2-
month diabetic rats involved mainly small nociceptive DRG
ganglion cells suggesting that this neuronal population is
aﬀected early as indicated by the morphometric analyses
of C-ﬁbers and previous ﬁndings of early deﬁcits of small
nociceptive neurons [33]. Over-activity of the p35/Cdk5
complex has also been associated with hyperglycemia and
has been implicated in the hyperphosphorylation of MAP
and tau in Alzheimer’s disease [49]. Interestingly, phospho-
tau was not signiﬁcantly altered in diabetic DRG’s. On the
other hand, p-GSK-3β expression increased with duration
of diabetes in parallel with decreased Akt-mediated phos-
phorylation of GSK-3 at Ser 9 [50, 51] and correlated with
increased phosphorylation of NF-H reﬂecting its aﬃnity to
NF-H [48]. Hence, impaired insulin and IGF-1 signaling
resulting in decreased GSK-3β (Ser 9) expression allows
for phosphorylation of p-GSK-3β, a potent phosphorylating
stress kinase, which has also been implicated in Alzheimer-
like changes in diabetes [51]. Diﬀerential phosphorylation
of neuroﬁlaments by Cdk5 and p-GSK-3β is known to
occur [48, 52]. Additional potential phosphorylating kinases
demonstrated here are p42/44 originating from deprived
MAPK signaling. The expression of phosphorylated p42/44
remained relatively constant throughout the observation
period, whereas the 54-kDA isoform of JNK was increased
only after 10-month of diabetes, which is in agreement
with the ﬁndings by Fernyhough et al. [21]. This is also
consistent with increased phosphorylation of NF-H at this
time point, since it provides a substrate for activated JNK
[53]. Activation of JNK has been associated with NGF and
insulin withdrawal [7, 54]. Demonstrated here for the ﬁrst
time several kinases become activated at diﬀerent stages
of diabetes and show aﬃnities to speciﬁc neuroﬁlamentExperimental Diabetes Research 9
Control BB/Wor
37 kd
49 kd
Phospho p44: ±0.25 ±0.38
Control BB/Wor Control BB/Wor
Phospho p42: ±0.34 ±0.56
P-p44: ±0.21 ± 0.18
P-p42: ±0.18 ± 0.34
P-p44: ±0.06 ±0.05
P-p42: ±0.13 ±0.12
2 month 10 month 7 month
∗∗∗ ∗∗
∗∗ ∗∗∗∗
∗
∗
1
1 1.53
1.77
1.3
1.49
1
1
1.62
1.85
1
1
(a)
49 kd
Total p44: ±0.07 ±0.06
Total p42: ±0.06 ±0.19
37 kd
T-p44: ±0.11 ±0.04
T-p42: ±0.07 ±0.11
T-p44: ±0.08 ±0.1
T-p42: ±0.09 ±0.08
1.1
1.12
1
1 1.06
1.03 1
1
0.94
0.88
1
1
(b)
49 kd
1±0.26 ±0.26 54kd:
46kd: 1±0.11 ±0.13
54kd
46kd
1±0.1 ±0.09 54kd:
46kd: 1±0.12 ±0.14
1±0.26 ± 0.02 54kd:
46kd: ±0.07 ±0.03
∗
∗ 1
1.4
1.11
0.91
0.88
1
1
(c)
37 kd
1±0.19 ±0.24  1 ±0.2  ±0.32 1±0.15 ±0.17 
∗∗
1.1 2 1.28
(d)
i) Phosphorylated/total p44
0
0.5
1
1.5
2
ii) Phosphorylated/total p42
0
0.5
1
1.5
2
2.5
3
∗
∗∗
∗∗
∗∗∗
∗∗∗
∗∗∗
2 mo          2 mo                
(
a
.
u
)
(
a
.
u
)
 10 mo 7 mo 
C C C C CC BB B BB B
10 mo  7 mo        
(e)
Figure 4: Protein expressions of activated kinases: (a) phosphorylated p42/44; (b) total p42/44; (c) phosphorylatead SAPK/JNK;. (d)
phosphorylated-p38; (e) Ratio of phosphorylated / total p44 and p42 at 2-month, 7-month and 10-month duration. Phophorylation ratio
was calculated by dividing phosphorylated protein level with respective total protein level. Results are means ± SD (n = 4). ∗P<. 05,
∗∗P<. 01, ∗∗∗P<. 005 and ∗∗∗∗P<. 001 versus respective control rats.10 Experimental Diabetes Research
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Figure 5: Expression of Cdk5 (a), total GSK-3β (b) and phosphorylated GSK-3β (c) in control and diabetic BB/Wor-rats at 2-month,
7-month, and 10-month duration. Results are means ± SD (n = 4). ∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001 versus respective control rats.
Linear regression analyses of the expression of GSK-3β and relative expression of phosphorylated NFH (e) and of the expression of Cdk5
and relative phosphorylated NFM (f). Note increased expression of GSK-3β and phosphorylated NFH with duration of diabetes, whereas
decreased expression of Cdk5 correlated with decreased phosphorylation of NFM with increasing diabetes duration.Experimental Diabetes Research 11
2 m
10 m
Cdk-5    
(a)
GSK-3β
(b)
Figure 6: Cdk5 (a) and p-GSK-3β (b) positive DRG neurons in 2-month and 10-month diabetic rats. Note frequent Cdk5 stainability of
small DRG neurons at 2-month (a), which tended to decrease with duration of diabetes. The number of p-GSK-3β positive DRG neurons
increased with duration of diabetes (b) and aﬀected ganglion cells of all sizes. The bar in the lower Figure 5(b) equals 35 μm and indicates
the magniﬁcation of all frames.
subunits whose expression also varies with diabetes duration
resulting in a dynamic picture of aberrant phosphorylation
changes with duration of diabetes.
As shown here β-III tubulin expression is severely dimin-
ished in acutely diabetic DRG neurons. Microtubules are
assembled from α and β tubulin heterodimers, organized in
a polarized fashion with a “minus” and “plus” end, at which
polymerization of tubulin dimers occurs [29]. The present
ﬁndings of decreased expression of β-III-tubulin there-
fore suggest perturbed polymerization of tubulin dimers.
Decreased GSK-3β by impaired insulin and IGF-1-signaling
is likely to inhibit MAP1B phosphorylation and hence
furtherinhibitthestabilityandassemblyoftubulinsessential
for axonal transport [27]. It therefore appears clear that
multiple aspects of expression and postranslational events
determining normal assembly of neuroskeletal constituents
are severely altered already during the acute stage of DPN
leading to impaired axonal maturation and degeneration.
The sequential phosphorylation of NF components as well
as destabilization of microtubules by several stress kinases
can be traced to impaired neurotrophic signaling activities
including those of insulin itself.
Thisnotionissupportedbytheﬁndingsthatreplacement
of insulinomimetic C-peptide, which normalizes insulin
signaling, corrects the expression of neurotrophic factors,
their receptors and neuroskeletal proteins as well as their
postranslational phosphorylation [23, 26, 33]. These eﬀects
translate into improved function and amelioration of
impaired maturation, axonal atrophy and loss [23, 34].
This construct may explain the fact that hyperinsulinemia
in the type 2 BBZDR/Wor-rat causes substantially milder
eﬀects on neurotrophic factors and their receptors [9, 36]
with signiﬁcantly milder functional and axonal structural
deﬁcits [2, 9]. The changing and dynamic perturbations of
the integrity of neuroskeletal proteins inevitably contribute
to axonal dysfunction and malalignment of neuroskeletal
components as previously demonstrated ultra-structurally
[55], eventually resulting in axonal atrophy and progressive
dying back of nerve ﬁbers as shown here.
Apart from progressive degenerative changes, an addi-
tional componet of neuropathy in type 1 diabetes, not
previously considered, is the potential impact of the pertur-
bations demonstrated here on peripheral nerve maturation.
As shown here, myelinated and unmyelinated ﬁber numbers
and sizes did not change in absolute values in diabetic
animals between 2 and 10-month, whereas both parameters
increased signiﬁcantly during the same time span in control
rats.Intheratperipheralnervematurationisonlycompleted
at 6month [56] and the corresponding age in humans is
beyond 25 years of age [57]. This suggests that metabolic
perturbations interfering with normal maturation processes
are likely to retard nerve growth and contribute to diabetic12 Experimental Diabetes Research
neuropathy both in humans and murine models, as has been
suggested for diabetic encephalopathy accompanying type 1
diabetes.
In summary, the present ﬁndings strongly suggest that
insulin and C-peptide deﬁciencies in type 1 DPN sets into
motion a dynamic cascade of events leading to suppression
of other neurotrophic factors together resulting in impaired
expression of neuroskeletal constituents. Simultaneous acti-
vation of stress-kinases leads sequentially to their aberrant
phosphorylation compromising axonal function, and pro-
moting progressive axonal growth deﬁcits, atrophy and loss,
the very hallmark of DPN.
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